Skip to main content

Table 2 (abstract P36). ISR-AEs over the EEP

From: 11th European Headache Federation Congress jointly with 31st Congress of the Italian Society for the Study of Headaches

 

Erenumab, mg

70 (N=2128)a

140 (N=1198)a

Subjects who experienced an ISR-AE, n (%)

130 (6.1)

50 (4.2)

Total time at risk summed across subjects, years

1738

649

Exposure-adjusted subject incidence rate per 100 subject-years

7.5

7.7

  1. aSubjects who received >1 dose level were counted in both dose levels